Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland.
about
Clinical use of proteasome inhibitors in the treatment of multiple myelomaA prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myelomaShort-course bortezomib-based retreatment for patients with multiple myeloma who had received bortezomib-thalidomide-dexamethasone (VTD) as an initial therapy: A single-center case series.Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.Clinical outcome of bortezomib retreatment in patients with relapsed or refractory multiple myeloma.Peripheral neuropathy outcomes and efficacy of subcutaneous bortezomib when combined with thalidomide and dexamethasone in the treatment of multiple myeloma.Pharmacokinetic study of bortezomib administered intravenously in Taiwanese patients with multiple myeloma.Drug rechallenge and treatment beyond progression--implications for drug resistance.European perspective on multiple myeloma treatment strategies: update following recent congressesThe Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple MyelomaProteasome inhibitors in multiple myeloma: 10 years later.The future of proteasome inhibitors in relapsed/refractory multiple myeloma.Treatment-related symptom management in patients with multiple myeloma: a review.Long-term disease control in a refractory multiple myeloma patient treated with bortezomib mono-therapy: a case report and review of literature.Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.Impaired bortezomib binding to mutant β5 subunit of the proteasome is the underlying basis for bortezomib resistance in leukemia cells.Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902).Efficacy and safety of bortezomib-based retreatment at the first relapse in multiple myeloma patients: A retrospective study.
P2860
Q28080999-EE053F06-96B8-4BCB-82CD-1DF85ED54235Q33405134-34F23779-312B-49F5-8BF1-D4431DF35769Q33409172-D5208ECE-E05E-4D76-8469-F352CC0F6712Q33412684-F547D2BD-47C6-45BA-8D2B-FA8266DB878EQ33414211-2F55D247-1BF5-4698-9E03-2581F3C133CCQ33418257-4210EBA6-3124-42FA-B1ED-258374209D58Q33419442-81AECFBE-9918-47AD-A4FF-3CEEADD007CAQ33437045-884D0ED4-4367-41D7-8EEA-795C74BC96ACQ33442798-0BABF0BC-8174-4597-ADBC-1D78E47AF82CQ35967416-2DC9529D-39FA-4949-9E07-C46FC8F2DE25Q35989943-02709434-4990-4426-9701-D1CAB2B2076FQ36444233-EB385E66-8610-4768-9C3B-20E8E11762ECQ38014395-570AD97E-9CE3-49AC-B93C-9F0FE57975F5Q38246060-2BC32513-9C7D-4B5B-A761-4F2828FD1AB9Q38342281-6BE88AE4-F1EF-4CC5-8081-096C6A29443CQ38697604-82932B43-4118-43A2-9DED-BFDDF5380D79Q39034873-17DD67AF-414F-4E11-B1CD-0D50E238094CQ39469395-18FA71AD-5425-419D-9100-6F0DC2C32FBDQ40818284-88ED1C37-EA7E-4C07-ACEF-AEB3ACFC79FEQ41705410-C68BA1E2-B7E9-4431-8CD6-154ED623638A
P2860
Bortezomib retreatment in relapsed multiple myeloma - results from a retrospective multicentre survey in Germany and Switzerland.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Bortezomib retreatment in rela ...... ey in Germany and Switzerland.
@en
Bortezomib retreatment in rela ...... ey in Germany and Switzerland.
@nl
type
label
Bortezomib retreatment in rela ...... ey in Germany and Switzerland.
@en
Bortezomib retreatment in rela ...... ey in Germany and Switzerland.
@nl
prefLabel
Bortezomib retreatment in rela ...... ey in Germany and Switzerland.
@en
Bortezomib retreatment in rela ...... ey in Germany and Switzerland.
@nl
P2093
P356
P1433
P1476
Bortezomib retreatment in rela ...... ey in Germany and Switzerland.
@en
P2093
A von Rohr
B Emmerich
I Hrusovsky
P304
P356
10.1159/000322866
P577
2010-01-01T00:00:00Z